

InvitroCue Limited

ASX: IVQ

Transforming Bio-Analytics

Corporate Structure:

Shares on issue: 444M
Market Cap: \$44.4 M

Directors:

Dr Steven Fang
Founder & Executive Director

Ms Jamie Khoo
Non-Executive Director &
Acting Chairwoman

Mr Chow-Yee Koh
Executive Director & Company
Secretary

Ms Ee Ting Ng
Non-Executive Director

Registered Office:
Level 2, 350 Kent St.
Sydney NSW 2000 Australia

Singapore Office:
11 Biopolis Way
Helios #12-07/08
Singapore 138667

Email:
contact@invitrocue.com

Website:
www.invitrocue.com

InvitroCue Fast Tracking Commercialisation of Imaging Technology Following Successful ASX Relisting

- **MOU signed with NCCS for collaborative research into HCC offers a significant potential market opportunity for IVQ**
- **Distribution agreement with ImageIQ greatly enhances IVQ's service offering**
- **InvitroCue maintains focus on further growth and development of cell-based assaying and digital pathology services**

8 February 2016, Singapore & Sydney: The Directors of InvitroCue Limited (formerly Bunuru Corporation Limited) (ASX: IVQ) ("InvitroCue" or "the Company") are pleased to provide shareholders with this update on the Company's operations following its recent successful re-quotation and commencement of trading on the ASX.

Reflecting the Company's strategy of fast tracking the commercialisation of its proprietary imaging technology, InvitroCue recently signed a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS).

Under the terms of the MOU, NCCS and IVQ will collaborate on research in the development of applications to improve treatment outcomes in primary liver cancer (Hepatocellular Carcinoma or HCC). The collaboration brings together NCCS's clinical and translational research in HCC developed over many years and IVQ's patented technology and expertise in biomedical quantitative image analysis.

It is anticipated that this research will enable clinicians to use non-invasive imaging to select the most appropriate therapy for individual patients, thereby greatly improving outcomes. If successful, InvitroCue would be well placed to leverage this market opportunity, especially given that some 80% of all cases of HCC occur in Asian regions¹. The Company also wishes to make a positive contribution to the lives of people afflicted by this disease.

Another recent notable development for Invitrocue was a distribution agreement the Company secured with US-based imaging software and contract research organisation, ImageIQ Inc. (ImageIQ). Under the terms of this agreement, InvitroCue can now provide its client base across Asia with access to ImageIQ's innovative web-based image analysis software platform, ImageQuantify.com.

This unique service offering will greatly enhance Invitrocue's product suite and aligns with the Company's mission statement of transforming the field of bioanalytics and imaging technologies through technological advancement. In addition, this alliance offers many potential synergies and benefits for both companies through further collaboration and research.

Commenting on these developments and the Company's recent relisting on the ASX, founder and now Executive Director of InvitroCue, Dr Steven Fang, said: "The ASX listing is a very important milestone for the Company, and the funds raised during the listing process have allowed us to now begin this process of fast tracking the further development and commercialisation of our image based assaying technology."

“We are extremely proud and honoured to be collaborating with the NCCS in this exciting research that will make progress towards achieving a positive difference for those afflicted by HCC, while also potentially delivering a significant market opportunity for the Company.”

“The pivotal distribution agreement we now have in place with ImageIQ is a great addition and enhancement to our broader service offering in image based assaying and analytics, and there are clear synergies and benefits to both parties through this alliance.”

“We believe there is significant untapped potential for both our cell-based assaying and digital pathology services in global markets, especially Singapore and Chinese markets. We expect to make further operational progress in the near term and I look forward to updating shareholders in this regard over the coming weeks and months.”

– ENDS –

¹Source: www.nccs.com.sg/Newsroom/NewsArticlesandReports/2016NewsArticlesandReports/Pages/Home.aspx?p=http://www.nccs.com.sg/Newsroom

For further information, please contact:

Dr Steven Fang
Executive Director
Steven.fang@invitrocue.com

Tee Rui Xian
Group Finance Manager
Ruixian.tee@invitrocue.com

Released through:

Adam Jarvis, Six Degrees Investor Relations: +61 427 297 736 or adam.jarvis@sdir.com.au